p.85 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e198 10. Abdalla M, Bolen SD, Brettler J, et al. Implementation strategies to improve blood pressure control in the United States: a scientific statement from the American Heart Association and American Medical Association. Hyperten sion. 2023;80:e143-e157. 11. He J, Ouyang N, Guo X, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401:928–938. 12. Law M, Wald N, Morris J, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427. 13. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combi nations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719. 14. Du LP, Cheng ZW, Zhang YX, et al. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hyperten sion: a meta-analysis. J Clin Hypertens (Greenwich) 2018;20:902–907. 15. Bellows BK, Ruiz-Negron N, Bibbins-Domingo K, et al. Clinic-based strate gies to reach United States Million Hearts 2022 blood pressure control goals. Circ Cardiovasc Qual Outcomes. 2019;12:e005624. 16. Ratanawongsa N, Zikmund-Fisher BJ, Couper MP, et al. Race, ethnicity, and shared decision making for hyperlipidemia and hypertension treatment: the DECISIONS survey. Med Decis Making. 2010;30:65S-76S. 17. Joint National Committee on Prevention Treatment of High Blood Pressure National High Blood Pressure Education Program. Report of the Joint Na tional Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Public Health Service, National Institutes of Health, National Heart and Lung; 1997. 18. US Food and Drug Administration. Approved drug products with therapeu tic equivalence evaluations| Orange book. Accessed September 30, 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/approveddrug-products-therapeutic-equivalence-evaluations-orange-book. 5.2.5 Antihypertensive Medication Adherence Strategies 1 Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medica tions: a meta-regression analysis. Int J Cardiol. 2016;216:104–109. 2. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evi dence from a meta-analysis. Clin Ther. 2002;24:302–316. 3. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of ran domized controlled trials. Arch Intern Med. 2004;164:722–732. 4. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hy pertension. 2010;55:399–407. 5. Du LP, Cheng ZW, Zhang YX, et al. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hyperten sion: a meta-analysis. J Clin Hypertens (Greenwich). 2018;20:902–907. 6. Webster R, Salam A, de Silva HA, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in pa tients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320:566–579. 7. Lauffenburger JC, Tesfaye H, Solomon DH, et al. Investigating the abil ity to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA. BMJ Open. 2023;13:e075840. 8. Nsiah I, Imeri H, Jones AC, et al. The impact of medication synchronization programs on medication adherence: a meta-analysis. J Am Pharm Assoc (2003). 2021;61:e202-e211. 9. Nguyen E, Sobieraj DM. The impact of appointment-based medication syn chronization on medication taking behaviour and health outcomes: a sys tematic review. J Clin Pharm Ther. 2017;42:404–413. 10. Al-Arkee S, Mason J, Lane DA, et al. Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis. J Med Internet Res. 2021;23:e24190. 11. Choudhry NK, Krumme AA, Ercole PM, et al. Effect of reminder devices on medication adherence: the REMIND randomized clinical trial. JAMA Intern Med. 2017;177:624–631. 12. Conversano C, Orru G, Pozza A, et al. Is mindfulness-based stress reduction effective for people with hypertension? A systematic review and meta-analysis of 30 years of evidence. Int J Environ Res Public Health. 2021;18:2882. 13. Morawski K, Ghazinouri R, Krumme A, et al. Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP randomized clinical trial. JAMA Intern Med. 2018;178:802– 809. 14. Van Truong P, Wulan Apriliyasari R, Lin MY, et al. Effects of self- management programs on blood pressure, self-efficacy, medication adher ence and body mass index in older adults with hypertension: meta-analysis of randomized controlled trials. Int J Nurs Pract. 2021;27:e12920. 15. Reeves L, Robinson K, McClelland T, et al. Pharmacist interventions in the management of blood pressure control and adherence to antihypertensive medications: a systematic review of randomized controlled trials. J Pharm Pract. 2021;34:480–492. 16. Xu H, Long H. The effect of smartphone app-based interventions for pa tients with hypertension: systematic review and meta-analysis. JMIR Mhealth Uhealth. 2020;8:e21759. 17. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihy pertensive drugs: a systematic review and meta-analysis. Medicine (Balti more). 2017;96:e5641. 18. Lee EKP, Poon P, Yip BHK, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc. 2022;11:e026582. 19. Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facili tates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63:834–835. 20. Pandey A, Raza F, Velasco A, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatmentresistant hypertension. J Am Soc Hypertens. 2015;9:420–426.e422. 21. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022;79:e1-e14. 22. Peeters LEJ, Kappers MHW, Hesselink DA, et al. Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial. J Hypertens. 2024;42:169–178. 23. Calderon-Larranaga A, Diaz E, Poblador-Plou B, et al. Non-adherence to antihypertensive medication: the role of mental and physical comorbidity. Int J Cardiol. 2016;207:310–316. 24. Alvarez C, Hines AL, Carson KA, et al. Association of perceived stress and discrimination on medication adherence among diverse patients with un controlled hypertension. Ethn Dis. 2021;31:97–108. 25. Bautista LE, Vera-Cala LM, Colombo C, et al. Symptoms of depression and anxiety and adherence to antihypertensive medication. Am J Hypertens. 2012;25:505–511. 26. Taft C, Hallberg I, Bengtsson U, et al. Links between blood pressure and medication intake, well-being, stress, physical activity and symptoms report ed via a mobile phone-based self-management support system: a cohort study in primary care. BMJ Open. 2018;8:e020849. 27. Stamoulis T, Dragioti E, Gouva M, et al. Unveiling the Nexus: depressive symptoms and medication adherence in hypertensive patients' self-care: a systematic review. Mater Sociomed. 2024;36:65–72. 28. Farhadi F, Aliyari R, Ebrahimi H, et al. Prevalence of uncontrolled hyper tension and its associated factors in 50-74 years old Iranian adults: a population-based study. BMC Cardiovasc Disord. 2023;23:318. 29. Qi M, Santos H, Pinheiro P, et al. Demographic and socioeconomic deter minants of access to care: a subgroup disparity analysis using new equityfocused measurements. PLoS One. 2023;18:e0290692. 30. Schesing KB, Chia R, Elwood B, et al. Assessment of patient and provider attitudes towards therapeutic drug monitoring to improve medication ad herence in low-income patients with hypertension: a qualitative study. BMJ Open. 2020;10:e039940. 31. Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual an tihypertensives in the UK (TIME study): a prospective, randomised, openlabel, blinded-endpoint clinical trial. Lancet. 2022;400:1417–1425. 32. Geiger C, Cramer H, Dobos G, et al. A systematic review and meta-analysis of mindfulness-based stress reduction for arterial hypertension. J Hum Hy pertens. 2023;37:161–169. 33. Lee EKP, Yeung NCY, Xu Z, et al. Effect and acceptability of mindfulnessbased stress reduction program on patients with elevated blood pressure or hypertension: a meta-analysis of randomized controlled trials. Hypertension. 2020;76:1992–2001. 34. Zaugg V, Korb-Savoldelli V, Durieux P, et al. Providing physicians with feedback on medication adherence for people with chronic dis eases taking long-term medication. Cochrane Database Syst Rev 2018;1:CD012042. Downloaded from http://ahajournals.org by on October 7, 2026